Tag: Big Pharma
-

GSK’s Nelkarmi Wins FDA Accelerated Approval for ALK-Positive Lung Cancer
GSK’s Nelkarmi (neladalkib) received FDA accelerated approval for certain adults with previously treated ALK-positive lung cancer. The decision rests on Phase 1/2 tumor response data, with further studies needed to confirm clinical benefit.
-

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, a Phase 3 candidate for wet AMD and diabetic macular edema. Early results against Vabysmo highlight differences in retinal imaging and leave open whether OLN324 can preserve vision with fewer injections.
-

FDA Approves Gazyva as First Treatment for Primary Membranous Nephropathy
The FDA approved Gazyva (obinutuzumab) to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression. In the Phase 3 MAJESTY trial, 36% of patients assigned to Gazyva achieved complete remission of proteinuria at week 104, compared with 6% assigned to tacrolimus, according to the FDA.
-

Bayer’s Sunharbo Wins FDA Approval for Secondary Stroke Prevention
Bayer’s Sunharbo (asundexian) is the first FDA-approved Factor XIa inhibitor. Its approval adds an oral treatment option alongside antiplatelet therapy for certain adults after a non-cardioembolic ischemic stroke or high-risk TIA. This article examines the clinical evidence, bleeding considerations and significance of the new drug class.
-

Genmab’s Petosemtamab–Keytruda Combination Improves Survival in Phase 3 Head and Neck Cancer Trial
Genmab’s petosemtamab plus Keytruda improved survival in Phase 3 head and neck cancer testing. A closer look at the findings and their meaning for patients.
-

GSK’s Hibsago Wins FDA Approval for Chronic Hepatitis B
GSK’s Hibsago (bepirovirsen) won FDA approval for selected adults with chronic hepatitis B. Explore its 19% functional cure result, RNA-targeting mechanism, treatment requirements and key safety risks.
-

Viatris and Opus’ Ryzumvi Wins FDA Approval for Adult Presbyopia
Ryzumvi wins FDA approval for adult presbyopia. Explore its pupil-reducing mechanism, Phase 3 results and the commercial challenges facing Viatris and Opus Genetics.
-

Roche’s Enspryng Wins FDA Approval for Thyroid Eye Disease
Roche’s Enspryng wins FDA approval for adult thyroid eye disease. Explore its IL-6 receptor blockade, antibody recycling technology, mixed Phase 3 results and the commercial implications of at-home treatment.

